Mariette Van Der Velden-Roesink

TargED started in September 2018 and is currently developing one biopharmaceutical product: MICROLYSE. MICROLYSE enzymatically breaks down blood clots in small blood vessels (i.e. the microvasculature), for which to date, no specific treatment exists. TargED pursues to receive market authorization for an orphan disease named Thrombotic Thrombocytopenic Purpura (TTP) that is characterized by life threatening attacks of microvascular thrombosis. However, MICROLYSE has the capacity to target all forms of microvascular thrombosis and could also be applied in early-stage macrovascular thrombosis as seen in heart attacks and stroke.

Citryll BV is a private pharmaceutical company based in Oss, the Netherlands that is dedicated to the development and commercialization of therapeutics that target NETosis and NETs. Target diseases include SLE, RA, vasculitis, cancer and fibrosis.

Allero Therapeutics is a Dutch biotech company that develops next generation immunotherapies for immune mediated disorders. Our goal is to develop novel targeted treatments that induce long-lasting antigen-specific tolerance. Our proprietary SOMIT (Specific Oromucosal Immunotherapy) technology combines a tolerance-inducing agent with novel oral patch mediated targeted delivery of specific antigens to the oral mucosa immune privilege.

MedEye was founded to improve medication safety in healthcare institutions. The company was founded in 2009 by three MIT graduates and is now headquartered in the Netherlands. It developed an innovative medication safety solution for bedside medication verification. MedEye shortens the time it takes nurses to verify and document medication administrations, increasing safety and efficiency. Through a combination of innovative hardware and software and seamless integration with hospital information systems, MedEye enables nurses to automatically verify medication at the bedside, thus ensuring that patients get the right medication, in the right dose and at the right time.

Lead Pharma is a pharmaceutical company focusing on the discovery and development of innovative medicines for the treatment of immune diseases and cancer. Lead Pharma is headquartered at Pivot Park, the biopharmaceutical life sciences campus in Oss, the Netherlands. We have fully equipped labs for all stages of drug discovery, including medicinal chemistry, cellular pharmacology, and molecular pharmacology, as well as an “in silico” lab for our computational chemistry, bioinformatics, and data mining activities. Lead Pharma has a qualified team of 29 people of which 10 hold a PhD degree and have long term experience working in large pharmaceutical companies, biotech companies and academia.

Synaffix BV is a biotech company that has established a proprietary, clinical-stage antibody-drug conjugate (ADC) technology platform that delivers best-in-class ADCs (safety and efficacy). Our platform is commercially validated by well over $7.6 billion in technology out-licensing deals with partners including ADC Therapeutics, Mersana Therapeutics, Shanghai Miracogen, Innovent Biologics, ProfoundBio and Kyowa Kirin. These partnerships have rapidly translated Synaffix technology into >20 ADCs currently in development by our partners, where 5 of these have already initiated Phase 1 clinical trials. Through the platform, we can rapidly generate best-in-class ADCs for our partners from any antibody and our patent portfolio protects our proprietary processes and any resulting Products through at least 2039. Additionally, Synaffix technology is being deployed to address unmet medical need in several multi-billion-dollar, high growth market segments such as immune cell engagers and targeted gene therapy. Synaffix BV was acquired by Lonza in May 2023.

Acerta Pharma is a European R&D centre of the AstraZeneca group dedicated to the discovery and development of novel innovative drugs for the treatment of haematological malignancies. The company began operations in 2013 with the vision of combining cutting edge science, unique covalent technology, and an experienced, dedicated team in order to deliver novel targeted therapies for patients with cancer. In 2016 AstraZeneca took a majority stake in the company and Acerta Pharma was fully acquired by AstraZeneca in 2021. As part of the significant expansion of our research activities in the Netherlands, we are in the process of building a new research centre in Pivot Park with state-of-the-art research laboratories for more than 140 researchers in Oss, the Netherlands. We are working to develop new treatment options for patients with specific types of blood cancer. Together with our R&D colleagues of AstraZeneca in Gaithersburg, San Francisco, Boston (US), Gothenburg (SE) and Cambridge (UK) we are committed to innovative drug discovery and development, especially in the field of haematological oncology.

Flindr Therapeutics, based in Oss in the Netherlands, is a private pre-clinical biotech company developing next-generation precision oncology treatments. The Company, previously called Immagene, was spun out of the Netherlands Cancer Institute (NKI) and Oncode Institute in 2020, by founders Prof Daniel Peeper, Prof Christian Blank and Dr Maarten Ligtenberg. Flindr is actively building a pipeline of highly promising, first-in-class precision oncology therapies identified through the ImmunoGram Drug Discovery Engine. It is backed by V-Bio Ventures, Johnson & Johnson Innovation – JJDC, Inc., QBIC Fund, Flanders Future Tech Fund, Curie Capital, Oncode Oncology Bridge Fund, Swanbridge, Innovatiefonds Noord Holland, and BOM. Flindr has entered into a research collaboration with the NKI, and the VIB (Flanders Institute of Biotechnology).

TargED started in September 2018 and is currently developing one biopharmaceutical product: MICROLYSE. MICROLYSE enzymatically breaks down blood clots in small blood vessels (i.e. the microvasculature), for which to date, no specific treatment exists. TargED pursues to receive market authorization for an orphan disease named Thrombotic Thrombocytopenic Purpura (TTP) that is characterized by life threatening attacks of microvascular thrombosis. However, MICROLYSE has the capacity to target all forms of microvascular thrombosis and could also be applied in early-stage macrovascular thrombosis as seen in heart attacks and stroke.

Citryll BV is a private pharmaceutical company based in Oss, the Netherlands that is dedicated to the development and commercialization of therapeutics that target NETosis and NETs. Target diseases include SLE, RA, vasculitis, cancer and fibrosis.

Allero Therapeutics is a Dutch biotech company that develops next generation immunotherapies for immune mediated disorders. Our goal is to develop novel targeted treatments that induce long-lasting antigen-specific tolerance. Our proprietary SOMIT (Specific Oromucosal Immunotherapy) technology combines a tolerance-inducing agent with novel oral patch mediated targeted delivery of specific antigens to the oral mucosa immune privilege.